MedPath

Gadobenic acid

Generic Name
Gadobenic acid
Brand Names
Multihance
Drug Type
Small Molecule
Chemical Formula
C22H28GdN3O11
CAS Number
113662-23-0
Unique Ingredient Identifier
15G12L5X8K
Background

Gadobenic acid (in the form of gadobenate dimeglumine) is an MRI contrast agent used primarily for MR imaging of the liver. It can also be used for visualizing the CNS and heart. In contrast to conventional extracellular fluid contrast agents, gadobenate dimeglumine is characterized by a weak and transient binding capacity to serum proteins. This binding leads to an increased relaxivity of gadobenate dimeglumine and, consequently, to a considerably increased signal intensity over that of other agents.

Indication

Gadobenate dimeglumine is indicated for use in magnetic resonance imaging (MRI) of the central nervous system in adult and pediatric patients in order to visualize lesions with abnormal blood-brain barrier or abnormal vascularity of the brain, spine, and associated tissues. It is also indicated for use in magnetic resonance angiography (MRA) to evaluate adults with known or suspected renal or aorto-ilio-femoral occlusive vascular disease.

Associated Conditions
Vascular Occlusion
Associated Therapies
-

Retrospective Study of MRI in Pediatric Patients

Completed
Conditions
Central Nervous System Disease
Central Nervous System Neoplasms
First Posted Date
2014-11-17
Last Posted Date
2016-07-19
Lead Sponsor
Bracco Diagnostics, Inc
Target Recruit Count
90
Registration Number
NCT02291822

Regadenoson Stress-MRI to Identify Coronary Artery Disease in Atrial Fibrillation Patients

Phase 2
Completed
Conditions
Atrial Fibrillation
Coronary Artery Disease
Interventions
First Posted Date
2012-10-19
Last Posted Date
2017-12-13
Lead Sponsor
University of Utah
Target Recruit Count
30
Registration Number
NCT01710254
Locations
🇺🇸

University of Utah, Salt Lake City, Utah, United States

Crossover Comparison of Two Gadolinium Contrast Agents for Use With MRA of Carotid, Renal and Peripheral Arteries

Phase 3
Completed
Conditions
Carotid, Aortic, Renal or Peripheral Artery Disease
Interventions
First Posted Date
2010-12-15
Last Posted Date
2012-01-05
Lead Sponsor
Bracco Diagnostics, Inc
Target Recruit Count
120
Registration Number
NCT01260636
Locations
🇨🇳

Radiology Department Zhongshan Hospital, Fudan University, Shanghai, China

Multihance Versus Magnevist in Breast MRI

Phase 3
Completed
Conditions
Breast Cancer
First Posted Date
2007-06-14
Last Posted Date
2010-07-15
Lead Sponsor
Bracco Diagnostics, Inc
Target Recruit Count
130
Registration Number
NCT00486473

Renal MRA Crossover Study Comparing Multihance to Another Contrast Agent

Phase 3
Completed
Conditions
Steno-occlusive Disease
Interventions
First Posted Date
2006-12-25
Last Posted Date
2023-08-01
Lead Sponsor
Bracco Diagnostics, Inc
Target Recruit Count
39
Registration Number
NCT00415805
Locations
🇮🇹

Bracco Imaging, S.p.A, Milan, Italy

A Pharmacokinetics Study of MultiHance in Pediatric Patients

Phase 1
Completed
Conditions
Central Nervous System Pathology
First Posted Date
2006-12-15
Last Posted Date
2008-01-11
Lead Sponsor
Bracco Diagnostics, Inc
Target Recruit Count
15
Registration Number
NCT00411931

Crossover Study With MultiHance vs a Comparator for Peripheral MRA

Phase 3
Completed
Conditions
Peripheral Vascular Disease
Interventions
First Posted Date
2006-12-06
Last Posted Date
2009-03-27
Lead Sponsor
Bracco Diagnostics, Inc
Target Recruit Count
100
Registration Number
NCT00408083
Locations
🇮🇹

Bracco Imaging, Milan, Italy

Multihance at 3 Tesla (3T) in Brain Tumors

Phase 4
Completed
Conditions
Brain Tumor
Interventions
Drug: Arm 2 - Magnevist
Drug: Multihance
First Posted Date
2006-11-06
Last Posted Date
2020-11-05
Lead Sponsor
Bracco Diagnostics, Inc
Target Recruit Count
46
Registration Number
NCT00395863
Locations
🇺🇸

Bracco Diagnostics, Inc., Princeton, New Jersey, United States

Safety and Efficacy of MultiHance in Pediatric Patients

Phase 3
Terminated
Conditions
Central Nervous System Diseases
Interventions
First Posted Date
2006-05-09
Last Posted Date
2010-10-22
Lead Sponsor
Bracco Diagnostics, Inc
Target Recruit Count
92
Registration Number
NCT00323310
Locations
🇺🇸

Bracco Diagnostics, Inc., Princeton, New Jersey, United States

A Study Comparing Two Magnetic Resonance Imaging (MRI) Contrast Agents in MRI of the Brain

Phase 4
Completed
Conditions
Brain Pathology
First Posted Date
2006-05-09
Last Posted Date
2008-01-23
Lead Sponsor
Bracco Diagnostics, Inc
Target Recruit Count
114
Registration Number
NCT00323102
Locations
🇺🇸

Bracco Diagnostics, Inc., Princeton, New Jersey, United States

© Copyright 2025. All Rights Reserved by MedPath